Incremental vs Conventional Hemodialysis for Kidney Failure
Trial Summary
What is the purpose of this trial?
The INCH-HD trial will test if incremental HD preserves the quality of life of patients and families and is a safe, practical, cost effective treatment option.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Incremental Hemodialysis for Kidney Failure?
Incremental hemodialysis, which adjusts treatment based on remaining kidney function, may improve quality of life and reduce healthcare costs compared to conventional hemodialysis. Studies suggest that survival rates for patients using incremental hemodialysis are similar to those using conventional methods, with potential socio-economic benefits.12345
Is incremental hemodialysis safe for patients with kidney failure?
Incremental hemodialysis is considered safe and may offer benefits like preserving kidney function and improving survival compared to full-dose dialysis. Studies show that survival rates are similar between incremental and conventional hemodialysis, especially for patients with low or moderate additional health issues.24678
How does incremental hemodialysis differ from conventional hemodialysis for kidney failure?
Incremental hemodialysis is unique because it tailors the frequency and duration of dialysis sessions based on a patient's remaining kidney function, starting with fewer sessions and increasing as needed, which can enhance quality of life and reduce healthcare costs compared to the standard thrice-weekly schedule of conventional hemodialysis.13459
Research Team
David Johnson, Prof
Principal Investigator
University of Queensland, Queensland Health
Peter Kerr, Prof
Principal Investigator
University of Queensland, Monash University
Andrea Viecelli, Dr
Principal Investigator
University of Queensland, Queensland Health
Charmaine Lok, Prof
Principal Investigator
University Health Network, Toronto
Eligibility Criteria
The INCH-HD trial is for adults over 18 who are starting hemodialysis (HD) as their first treatment for kidney failure. They must be able to consent to the study and likely stay on HD for at least a year. People with urine output less than half a liter per day can't join.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either incremental HD (twice weekly) or conventional HD (thrice weekly) based on randomization
Follow-up
Participants are monitored for safety and effectiveness after treatment
Extension
Continued monitoring and assessment of health-related quality of life and other outcomes
Treatment Details
Interventions
- Conventional HD
- Incremental HD
Conventional HD is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
- Acute kidney injury
- Chronic kidney disease
- End-stage renal disease
- Uremic encephalopathy
- Pericarditis
- Life-threatening hyperkalemia
- Refractory acidosis
- Hypervolemia causing end-organ complications
- Acute kidney injury
- Chronic kidney disease
- End-stage renal disease
- Uremic encephalopathy
- Pericarditis
- Life-threatening hyperkalemia
- Refractory acidosis
- Hypervolemia causing end-organ complications
- Acute kidney injury
- Chronic kidney disease
- End-stage renal disease
- Uremic encephalopathy
- Pericarditis
- Life-threatening hyperkalemia
- Refractory acidosis
- Hypervolemia causing end-organ complications
- Acute kidney injury
- Chronic kidney disease
- End-stage renal disease
- Uremic encephalopathy
- Pericarditis
- Life-threatening hyperkalemia
- Refractory acidosis
- Hypervolemia causing end-organ complications
- Acute kidney injury
- Chronic kidney disease
- End-stage renal disease
- Uremic encephalopathy
- Pericarditis
- Life-threatening hyperkalemia
- Refractory acidosis
- Hypervolemia causing end-organ complications
- Acute kidney injury
- Chronic kidney disease
- End-stage renal disease
- Uremic encephalopathy
- Pericarditis
- Life-threatening hyperkalemia
- Refractory acidosis
- Hypervolemia causing end-organ complications
Find a Clinic Near You
Who Is Running the Clinical Trial?
The University of Queensland
Lead Sponsor
Medical Research Future Fund
Collaborator
Queensland Health
Collaborator
Canadian Institutes of Health Research (CIHR)
Collaborator